The trials included about 470 participants, showing a substantial reduction in sleep apnea episodes compared to a placebo. Common side effects were mild to moderate gastrointestinal issues, mostly occurring during the initial treatment phase.

The drug costs around $1,060 per month without insurance, but the company offers discounts and a lower-cost version administered via a traditional syringe. This approval may help expand Medicare coverage for certain cases.

OSA affects approximately 30 million people in the U.S. and is closely linked to obesity. Clinical trials demonstrated significant improvements in symptoms with Zepbound, along with up to 20% weight loss and reductions in blood pressure and inflammation.